BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 7999811)

  • 1. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
    Raja R; Bloom E; Johnson R; Goldstein M
    Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
    Raja R; Bloom E; Johnson R
    Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin with oral iron in peritoneal and hemodialysis patients. A comparison in an inner city population.
    Raja R; Bloom E; Goldstein M; Johnson R
    ASAIO J; 1993; 39(3):M578-80. PubMed ID: 8268603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of iron saturation for erythropoietin responsiveness in chronic peritoneal dialysis.
    Jonnalagadda V; Bloom EJ; Raja RM
    Adv Perit Dial; 1997; 13():113-5. PubMed ID: 9360662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: a prospective, cross-over trial.
    Ahsan N
    Adv Perit Dial; 2000; 16():80-4. PubMed ID: 11045266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of intramuscular versus subcutaneous erythropoietin for the treatment of anemia in CAPD patients.
    Abreo K; Lubom JA; Collier L; Fleming D; Work J
    Adv Perit Dial; 1994; 10():124-8. PubMed ID: 7999809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficiency of fractionated parenteral iron treatment in CAPD patients.
    Akcicek F; Ozkahya M; Cirit M; Ok E; Unsal A; Toz H; Celik A; Atabay G; Basci A
    Adv Perit Dial; 1997; 13():109-12. PubMed ID: 9360661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical and economic significance of iron replacement in anemia treated with recombinant human erythropoietin in patients on hemodialysis].
    Vanková S; Safárová R; Horácková M; Herink J; Rychlík I; Bahbouh R; Půtová I
    Cas Lek Cesk; 2001 Apr; 140(7):209-13. PubMed ID: 11374225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of bolus intraperitoneal iron dextran in continuous ambulatory peritoneal dialysis or continuous cyclic peritoneal dialysis patients receiving recombinant human erythropoietin.
    Mars RL; Moles K; Pope K; Hargrove P
    Adv Perit Dial; 1999; 15():60-4. PubMed ID: 10682073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients.
    Fishbane S; Lynn RI
    Clin Nephrol; 1995 Oct; 44(4):238-40. PubMed ID: 8575123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin resistance in patients on continuous ambulatory peritoneal dialysis.
    Nakamoto H; Kanno Y; Okada H; Suzuki H
    Adv Perit Dial; 2004; 20():111-6. PubMed ID: 15384808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron dextran treatment in peritoneal dialysis patients on erythropoietin.
    Suh H; Wadhwa NK
    Adv Perit Dial; 1992; 8():464-6. PubMed ID: 1361849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
    Stojimirović B; Grujić-Adanja G
    Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with subcutaneous erythropoietin in CAPD patients.
    Bailie GR; Plitnick R; Eisele G; Clement C; Rasmussen R
    Adv Perit Dial; 1991; 7():292-5. PubMed ID: 1680449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
    Lui SF; Law CB; Ting SM; Li P; Lai KN
    Clin Nephrol; 1991 Nov; 36(5):246-51. PubMed ID: 1752075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ITDI is the preferred treatment for iron supplementation in rHuEpo-treated anemic PD patients.
    Ahsan N
    Adv Perit Dial; 1998; 14():228-31. PubMed ID: 10649730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of iron supply for erythropoietin therapy.
    Sunder-Plassmann G; Hörl WH
    Nephrol Dial Transplant; 1995 Nov; 10(11):2070-6. PubMed ID: 8643170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
    Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.